A citation-based method for searching scientific literature

Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine.
Kenichi Fukumoto, Manoela V Fogaça, Rong-Jian Liu, Catharine Duman, Taro Kato, Xiao-Yuan Li, Ronald S Duman. Proc Natl Acad Sci U S A 2019
Times Cited: 99



Effects of a ketamine metabolite on synaptic NMDAR function.
Kanzo Suzuki, Elena Nosyreva, Kevin W Hunt, Ege T Kavalali, Lisa M Monteggia. Nature 2017
Times Cited: 110




List of shared articles



Times cited

(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
Panos Zanos, Jaclyn N Highland, Xin Liu, Timothy A Troppoli, Polymnia Georgiou, Jacqueline Lovett, Patrick J Morris, Brent W Stewart, Craig J Thomas, Scott M Thompson,[...]. Br J Pharmacol 2019
45

Subcritical Fluid Chromatography at Sub-Ambient Temperatures for the Chiral Resolution of Ketamine Metabolites with Rapid-Onset Antidepressant Effects.
Robert K Hofstetter, Felix Potlitz, Lukas Schulig, Simon Kim, Mahmoud Hasan, Andreas Link. Molecules 2019
12

Ketamine: Neuroprotective or Neurotoxic?
Divya Choudhury, Anita E Autry, Kimberley F Tolias, Vaishnav Krishnan. Front Neurosci 2021
13

Antidepressant actions of ketamine engage cell-specific translation via eIF4E.
Argel Aguilar-Valles, Danilo De Gregorio, Edna Matta-Camacho, Mohammad J Eslamizade, Abdessattar Khlaifia, Agnieszka Skaleka, Martha Lopez-Canul, Angelica Torres-Berrio, Sara Bermudez, Gareth M Rurak,[...]. Nature 2021
35

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.
Eric W Lumsden, Timothy A Troppoli, Scott J Myers, Panos Zanos, Yasco Aracava, Jan Kehr, Jacqueline Lovett, Sukhan Kim, Fu-Hua Wang, Staffan Schmidt,[...]. Proc Natl Acad Sci U S A 2019
79

A hypothesis of monoamine (5-HT) - Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery.
Yun-Feng Li. Pharmacol Ther 2020
35

Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketamines.
Jaclyn N Highland, Patrick J Morris, Kylie M Konrath, Lace M Riggs, Natalie R Hagen, Panos Zanos, Chris F Powels, Ruin Moaddel, Craig J Thomas, Amy Q Wang,[...]. ACS Chem Neurosci 2022
5

Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression.
Ethan Ponton, Gustavo Turecki, Corina Nagy. Int J Neuropsychopharmacol 2022
2

Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition.
Bernhard Luscher, Mengyang Feng, Sarah J Jefferson. Adv Pharmacol 2020
9

Rodent ketamine depression-related research: Finding patterns in a literature of variability.
Andrew J Polis, Paul J Fitzgerald, Pho J Hale, Brendon O Watson. Behav Brain Res 2019
20

Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.
Jaclyn N Highland, Panos Zanos, Lace M Riggs, Polymnia Georgiou, Sarah M Clark, Patrick J Morris, Ruin Moaddel, Craig J Thomas, Carlos A Zarate, Edna F R Pereira,[...]. Pharmacol Rev 2021
33

Ketamine metabolite (2R,6R)-hydroxynorketamine enhances aggression via periaqueductal gray glutamatergic transmission.
Lichao Ye, Chih-Yuan Ko, Yuting Huang, Chen Zheng, Yanfang Zheng, Dylan Chou. Neuropharmacology 2019
16

Ketamine-induced regulation of TrkB-GSK3β signaling is accompanied by slow EEG oscillations and sedation but is independent of hydroxynorketamine metabolites.
Samuel Kohtala, Wiebke Theilmann, Marko Rosenholm, Heidi K Müller, Paula Kiuru, Gregers Wegener, Jari Yli-Kauhaluoma, Tomi Rantamäki. Neuropharmacology 2019
13

Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search.
Jordi Bonaventura, Juan L Gomez, Meghan L Carlton, Sherry Lam, Marta Sanchez-Soto, Patrick J Morris, Ruin Moaddel, Hye Jin Kang, Panos Zanos, Todd D Gould,[...]. Mol Psychiatry 2022
6

Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action.
Eero Castrén, Lisa M Monteggia. Biol Psychiatry 2021
79

The molecular pathophysiology of depression and the new therapeutics.
Haihua Tian, Zhenyu Hu, Jia Xu, Chuang Wang. MedComm (2020) 2022
3

Resolvins as potential candidates for the treatment of major depressive disorder.
Satoshi Deyama, Masabumi Minami, Katsuyuki Kaneda. J Pharmacol Sci 2021
8

Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant.
Songbai Xu, Xiaoxiao Yao, Bingjin Li, Ranji Cui, Cuilin Zhu, Yao Wang, Wei Yang. Front Pharmacol 2022
5

Prelimbic cortex miR-34a contributes to (2R,6R)-hydroxynorketamine-mediated antidepressant-relevant actions.
Lichao Ye, Xueling Xiao, Yuanyuan Xu, Chen Zheng, Si Chen, Tao Luo, Zhenlong Li, Yuze Du, Yilin Yuan, Linyi Li,[...]. Neuropharmacology 2022
2

(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.
Lace M Riggs, Yasco Aracava, Panos Zanos, Jonathan Fischell, Edson X Albuquerque, Edna F R Pereira, Scott M Thompson, Todd D Gould. Neuropsychopharmacology 2020
27

Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function.
Ronald S Duman, Ryota Shinohara, Manoela V Fogaça, Brendan Hare. Mol Psychiatry 2019
72

Ketamine: The final frontier or another depressing end?
Omar K Sial, Eric M Parise, Lyonna F Parise, Tamara Gnecco, Carlos A Bolaños-Guzmán. Behav Brain Res 2020
16

Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma.
Greg I Elmer, Jenica D Tapocik, Cheryl L Mayo, Panos Zanos, Todd D Gould. Pharmacol Biochem Behav 2020
8

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.
Panos Zanos, Jaclyn N Highland, Brent W Stewart, Polymnia Georgiou, Carleigh E Jenne, Jacqueline Lovett, Patrick J Morris, Craig J Thomas, Ruin Moaddel, Carlos A Zarate,[...]. Proc Natl Acad Sci U S A 2019
77

Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants.
Ronald S Duman, Satoshi Deyama, Manoela Viar Fogaça. Eur J Neurosci 2021
80

A synaptic locus for TrkB signaling underlying ketamine rapid antidepressant action.
Pei-Yi Lin, Z Zack Ma, Melissa Mahgoub, Ege T Kavalali, Lisa M Monteggia. Cell Rep 2021
17

CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity.
Thi Mai Loan Nguyen, Josephine Cecelia McGowan, Alain M Gardier. Neuropharmacology 2022
2

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.
Chun Yang, Jianjun Yang, Ailin Luo, Kenji Hashimoto. Transl Psychiatry 2019
92

A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801.
Patrick J Morris, Richard D Burke, Alok K Sharma, Daniel C Lynch, Leslie E Lemke-Boutcher, Shiny Mathew, Ikram Elayan, Deepa B Rao, Todd D Gould, Carlos A Zarate,[...]. Neurotoxicol Teratol 2021
7

Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and Toxicity.
Eric S Schwenk, Basant Pradhan, Rohit Nalamasu, Lucas Stolle, Irving W Wainer, Michael Cirullo, Alexander Olson, Joseph V Pergolizzi, Marc C Torjman, Eugene R Viscusi. Curr Pain Headache Rep 2021
2

Mechanisms of ketamine and its metabolites as antidepressants.
Evan M Hess, Lace M Riggs, Michael Michaelides, Todd D Gould. Biochem Pharmacol 2022
16


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy